|
Feb 15
|
Jim Cramer Comments on Merck & Co., Inc. (MRK) and Its China Woes
|
|
Feb 13
|
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
|
|
Feb 13
|
Merck & Co., Inc. (MRK): A Bull Case Theory
|
|
Feb 13
|
US pharma giant Merck backs healthcare marketplace HD in Southeast Asia
|
|
Feb 12
|
Why Merck & Co., Inc. (MRK) is Declining
|
|
Feb 11
|
Jim Cramer on Merck & Co., Inc. (MRK): ‘Drug Stocks Are Really Getting Hurt’
|
|
Feb 11
|
Health Canada Approves Merck's KEYTRUDA® (pembrolizumab) for the treatment of adult patients with resectable Stage II, IIIA, or IIIB (T3-4N2) non-small cell lung carcinoma (NSCLC) in combination with platinum-containing chemotherapy as neoadjuvant trea...
|
|
Feb 11
|
In the crowded cardio space, it’s David vs. Goliath for small biotechs
|